中国卒中杂志2016，Vol.11Issue(8)：697-703,7.DOI:10.3969/j.issn.1673-5765.2016.08.017
血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗急性缺血性卒中的研究进展
Advance of Glycoprotein IIb/IIIa Antagonist in Acute Ischemic Stroke
摘要
Abstract
Platelet activation plays an important role in thrombosis. Although intravenous alteplase (rtPA) is the standard therapy for acute ischemic stroke (AIS), the role of antiplatelet alone or combined with thromblysis has always been explored. Glycoprotein (GP) IIb/IIIa antagonist inhibits platelet aggregation effectively through the ifnal common pathway. Efifcacy and safety of GP IIb/IIIa antagonist have been conifrmed in acute coronary syndrome (ACS), while results have been less consistent in AIS. Hence this paper is to make a review of clinical researches on GP IIb/IIIa antagonist in AIS.关键词
血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂/抗血小板治疗/急性缺血性卒中Key words
Glycoprotein IIb/IIIa antagonist/Anti-platelet therapy/Acute ischemic stroke引用本文复制引用
林露,张猛..血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂治疗急性缺血性卒中的研究进展[J].中国卒中杂志,2016,11(8):697-703,7.基金项目
重庆市社会民生科技创新专项 （）
